Select Advanced Solid Tumors

Oncology
5
Pipeline Programs
3
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
4
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Immunocore
ImmunocoreOXFORDSHIRE, United Kingdom
3 programs
3
BrenetafuspPhase 1/21 trial
IMC-C103CPhase 1/21 trial
IMCnyesoPhase 1/21 trial
Active Trials
NCT04262466Active Not Recruiting410Est. Dec 2027
NCT03973333Withdrawn0Est. Sep 2023
NCT03515551Terminated29Est. May 2021
KSQ Therapeutics
KSQ TherapeuticsMA - Lexington
1 program
1
CyclophosphamidePhase 1/21 trial
Active Trials
NCT06598371RecruitingEst. Aug 2041
CDR-Life
CDR-LifeSwitzerland - Zurich
1 program
1
CDR404Phase 11 trial
Active Trials
NCT06402201RecruitingEst. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
KSQ TherapeuticsCyclophosphamide
ImmunocoreBrenetafusp
ImmunocoreIMC-C103C
ImmunocoreIMCnyeso
CDR-LifeCDR404

Clinical Trials (5)

Total enrollment: 439 patients across 5 trials

NCT06598371KSQ TherapeuticsCyclophosphamide

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Start: Nov 2024Est. completion: Aug 2041
Phase 1/2Recruiting
NCT04262466ImmunocoreBrenetafusp

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Start: Feb 2020Est. completion: Dec 2027410 patients
Phase 1/2Active Not Recruiting
NCT03973333ImmunocoreIMC-C103C

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Start: May 2019Est. completion: Sep 20230
Phase 1/2Withdrawn
NCT03515551ImmunocoreIMCnyeso

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Start: Jun 2018Est. completion: May 202129 patients
Phase 1/2Terminated
NCT06402201CDR-LifeCDR404

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Start: May 2024Est. completion: Dec 2027
Phase 1Recruiting

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
2h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 439 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)